The depressed company could use Mylotarg as a stepping stone in AML.

The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

Acquiring Gracell at an 86% premium raises hopes that the biotech markets are bottoming out after a turbulent two years.

Nine years after a groundbreaking deal with Pfizer, Cellectis goes to AstraZeneca for a fresh lease of life.

Curiously, however, higher dosing does not seem to be the answer to the company’s relapse problem.